Dr Reddy’s Launches ‘Nerivo’ in Germany After Tasting Success in India

In 2023, Dr Reddy's launched Nerivio in India alongside its innovative patient support program, 'M-Free.'

Global pharma player, Dr Reddy's Laboratories has introduced Nerivio, a non-invasive migraine management wearable device, in Germany.

This move comes after the successful launch of Nerivio in India last year, accompanied by the patient support program 'M-Free.'

After acquiring Germany-based Betapharm in 2006, Dr Reddy’s has now set its foot in expanding its digital therapeutics business with the introduction of Nerivio.

Moreover, Nerivio, approved by the US FDA, also received CE-mark certification in Europe, ensuring its adherence to rigorous safety and efficacy standards.

The device gained prominence after its presentation at the 2023 DGN Kongress by the German Association of Neurology in Berlin and the 17th European Headache Congress in Barcelona, Spain.

Further, Dr Reddy's will unveil and introduce Nerivio at the annual congress of the Neurological Association of South Africa on April 17, 2024.

In May 2024, Nerivio is slated for presentation at the International Headache Society 2024 iHEAD meeting in Berlin, Germany. Following this, Dr Reddy's plans to introduce Nerivio in Spain and the UK in the following months.

In the previous year, Dr Reddy's entered into an exclusive agreement with Theranica, a prescribed digital therapeutics company. They specialize in developing advanced neuromodulation devices for migraine and other pain conditions. This agreement focuses on the marketing and distribution of Nerivio in multiple markets.

Migraine: A Global Health Challenge

Migraine remains a pervasive global health concern, affecting approximately 30% of adults for 15 or more days per month. With a prevalence ranging from 14-15% globally, migraine contributes significantly to global ill health, accounting for 4.9% of years lived with disability.

The burden of migraine disproportionately affects women, with statistics revealing a higher prevalence among females. In Germany, an estimated 8 to 10 million people suffer from migraines, with women constituting 14.8% of sufferers compared to 6.0% of men.

In India, where approximately 213 million individuals endure migraines, women represent around 60% of sufferers.

Patient-Centric Approach: M-Free Program

In 2023, Dr Reddy's launched Nerivio in India alongside its innovative patient support program, 'M-Free.' This comprehensive initiative aims to enhance the patient journey by offering a range of value-added services.

Per the company, from onboarding and counseling to doorstep delivery and flexible payment options, M-Free ensures seamless access to Nerivio. Moreover, the program incorporates holistic approaches such as nutritionist consultations, yoga, and meditation sessions, aligning with lifestyle modifications recommended for migraine management.

"At a time when discussions surrounding migraine often revolve around its portrayal as a women's health issue, the utilization of technology and drug-free solutions for migraine relief, challenges in managing migraine during child-bearing years, and distinguishing migraine from other types of headaches, we are pleased to introduce our clinically-proven digital therapeutics product, Nerivio, to patients in our targeted markets," said MV Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy's.

Ramana further emphasized the encouraging response Nerivio received in India, where it was recommended by neurologists and provided relief to migraine patients. He believes Nerivio addresses a genuine clinical need and has the potential to reduce the pill burden for migraine sufferers.